Pulmonary Arterial Hypertension: all 773 studies

Page 5 of 8. Open to participants first (142), then studies with results posted, then the rest; newest registration first within each.

• Effect of CS1 in Subjects With Pulmonary Arterial HypertensionCompletedNCT05224531Phase 2
• A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy SubjectsCompletedNCT05208814Phase 1
• A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionActive, not recruitingNCT05203510Phase 4
• Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver FunctionCompletedNCT05185011Phase 1
• Dapagliflozin in Pulmonary Arterial HypertensionCompletedNCT05179356Phase 2
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionCompletedNCT05147805Phase 2
• Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial HypertensionCompletedNCT05124015
• Evaluate Real-World Use of Next Generation Infusion Pumps to Administer RemodulinTerminatedNCT05060315
• Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial HypertensionCompletedNCT05056532
• A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)TerminatedNCT05036135Phase 2/3
• REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study)Status unknownNCT05029167Not applicable
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of SildenafilCompletedNCT04994860Phase 1
• Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsCompletedNCT04994119Phase 1
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of BosentanCompletedNCT04991207Phase 1
• Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058TerminatedNCT04991194Phase 1
• Absorption, Distribution, Metabolism and Excretion of BIA 5-1058CompletedNCT04991181Phase 1
• Effect of Food on BIA 5-1058CompletedNCT04991155Phase 1
• Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)CompletedNCT04968210
• A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) ParticipantsTerminatedNCT04955990Phase 4
• Apabetalone for Pulmonary Arterial HypertensionStatus unknownNCT04915300Phase 2
• Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation SolutionCompletedNCT04903730Phase 1
• Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility StudyCompletedNCT04884971Phase 1
• Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)TerminatedNCT04816604Phase 2
• A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)CompletedNCT04813926
• Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial HypertensionCompletedNCT04808830
• Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial HypertensionCompletedNCT04787445
• Observational Study of Actigraphy in Pediatric Pulmonary Arterial HypertensionCompletedNCT04745000
• Medication Reconciliation in Pulmonary HypertensionCompletedNCT04744584
• A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILDActive, not recruitingNCT04691154Phase 3
• Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk ScoreStatus unknownNCT04677608
• Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedNCT04675944Phase 1
• Right Atrial Fibrosis in Pulmonary HypertensionCompletedNCT04663230
• Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary HypertensionCompletedNCT04663217
• Functional Exercise Tests in Patients With Systemic SclerosisStatus unknownNCT04650659
• Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial HypertensionStatus unknownNCT04589390Phase 2
• Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial HypertensionCompletedNCT04578223
• A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or SelexipagCompletedNCT04567602
• Remote Exercise Program Delivery Using a Mobile Application for Pulmonary Arterial HypertensionWithdrawnNCT04559516Not applicable
• Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial HypertensionStatus unknownNCT04528056Phase 1/2
• A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy VolunteersCompletedNCT04505137Phase 1
• A Study of GMA301 in Subjects With Pulmonary Arterial HypertensionStatus unknownNCT04503733Phase 1
• Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial HypertensionStatus unknownNCT04489251
• Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial HypertensionCompletedNCT04483115Phase 2
• Serum Bio-markers in Pulmonary HypertensionCompletedNCT04472533
• HRV as a Marker of Treatment Response in PAH Arterial HypertensionCompletedNCT04451850
• Anxiety Self-management Intervention for Pulmonary HypertensionStatus unknownNCT04450862Not applicable
• Positioning Imatinib for Pulmonary Arterial HypertensionActive, not recruitingNCT04416750Phase 2
• Impact of Aerobic Training on Sleep Quality and Aerobic Fitness in Male Patients With Pulmonary Artery HypertensionCompletedNCT04337671Not applicable
• Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial HypertensionStatus unknownNCT04309838
• DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical TrialCompletedNCT04282434
• TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAHWithdrawnNCT04280523
• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionActive, not recruitingNCT04273945Phase 3
• Pilot Randomized Trial of Ambulatory Exercise in Pulmonary HypertensionWithdrawnNCT04254289Not applicable
• Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and MetabolismStatus unknownNCT04241497Not applicable
• The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With HypoxemiaCompletedNCT04207593Phase 2
• Inspiratory Muscle Training in Pulmonary Arterial HypertensionStatus unknownNCT04197388Not applicable
• Biomarkers in Pediatric Congenital Heart Disease and PAHStatus unknownNCT04130243
• Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary HypertensionCompletedNCT04104490
• Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus InfectionCompletedNCT04094272
• Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot StudyTerminatedNCT04090866
• BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial HypertensionCompletedNCT04086537
• Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial HypertensionCompletedNCT04076241Not applicable
• Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial HypertensionStatus unknownNCT04055415Phase 1/2
• CXA-10 Study in Subjects With Pulmonary Arterial HypertensionTerminatedNCT04053543Phase 2
• Long-term Outcomes of Pregnant Women With PAHStatus unknownNCT04053296
• Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606CompletedNCT04041648Phase 1
• Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)TerminatedNCT04008550Not applicable
• Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of TreprostinilActive, not recruitingNCT03992755Phase 3
• Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAHCompletedNCT03979482
• Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort StudyStatus unknownNCT03977428
• The PAH Platform for Deep Phenotyping in Korean SubjectsStatus unknownNCT03933579
• 4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart DiseaseCompletedNCT03928002Not applicable
• Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial HypertensionCompletedNCT03926793Phase 1
• A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)TerminatedNCT03924154Phase 2
• miRNA and Myokines in Patients With PAHWithdrawnNCT03905083Not applicable
• A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic SclerosisCompletedNCT03889509
• Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of TreprostinilTerminatedNCT03884465Phase 2
• Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the LungsCompletedNCT03863990
• Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAHStatus unknownNCT03841344Not applicable
• Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)Active, not recruitingNCT03838445Not applicable
• Implantable System for Remodulin Post-Approval StudyWithdrawnNCT03833323
• Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)Status unknownNCT03819777
• Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial HypertensionStatus unknownNCT03810443Not applicable
• Upfront Combination Pulmonary Arterial Hypertension TherapyStatus unknownNCT03809156Phase 4
• Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004TerminatedNCT03795428Phase 2
• Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial HypertensionWithdrawnNCT03789643Phase 2
• Olaparib for PAH: a Multicenter Clinical TrialTerminatedNCT03782818Phase 1/2
• This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)CompletedNCT03754660Phase 1
• Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During ExerciseCompletedNCT03718780Not applicable
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058CompletedNCT03708146Phase 1
• PET/MRI in PAH PatientsCompletedNCT03688698
• Oxygen Treatment and Pulmonary Arterial HypertensionStatus unknownNCT03683082Not applicable
• Apabetalone for Pulmonary Arterial Hypertension: a Pilot StudyCompletedNCT03655704Early Phase 1
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsCompletedNCT03626688Phase 3
• Neuromuscular Electrical Stimulation in Pulmonary Arterial HypertensionCompletedNCT03612115Not applicable
• Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled NitricWithdrawnNCT03602781Phase 3
• Insulin- and Glucose Metabolism in Pulmonary Arterial HypertensionCompletedNCT03584607
• Surgical Valvuloplasty for Congenital Mitral InsufficiencyStatus unknownNCT03567668
• Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAHTerminatedNCT03556020Phase 2
• Combined Use of Radiofrequency-ablation and Balloon-septostomy in the Creation of a Stable Inter-atrial CommunicationStatus unknownNCT03554330Not applicable

← Pulmonary Arterial Hypertension overview